SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update

Following reporting of results for the ELPIS II Phase 2b clinical trial, the Company has requested a

LGVNLGVNR

Related stories